| Name | Title | Contact Details |
|---|
Cabaco Marine International is a Santa Barbara, CA-based company in the Business Services sector.
Founded in 1953, REDW is a Top 200 Accounting Firm and one of the Southwest`s 10 largest CPA and business advisory firms. With offices in Albuquerque, Phoenix, and Edmond, OK, REDW is home to more than 200 employees. We are a firm that believes in doing the right thing, that Integrity Counts®. Integrity matters in building the foundation for a firm that lasts, one we`re proud to represent. Knowing that diversity combined with inclusive practices makes us stronger, we`re weaving different voices, perspectives, values and backgrounds into a cohesive culture that is greater than the sum of its parts—a culture that invites and celebrates the talents and experiences in our teams, communities and clients. Working as partners with our clients, we look beyond conventional wisdom to find practical, cost-effective solutions and strategies for helping capitalize on emerging business opportunities and challenges. Our business advisory services range from audit and assurance to cybersecurity, data and business intelligence, disputes, human resources consulting, management and accounting, retirement plan administration, software, tax, transaction, valuation, and wealth management. While REDW is large and sophisticated enough to handle the most complex matters, we are also small and nimble enough to offer the personal, hands-on service clients want from their CPA firm. Our collaborative approach to business has earned us steadfast client loyalty and a national reputation for excellence.
Practical Strategy is a Chevy Chase, MD-based company in the Business Services sector.
Metsera is a clinical-stage biopharmaceutical company based in New York City, dedicated to developing innovative treatments for obesity and metabolic diseases. Founded in 2022 by Population Health Partners and ARCH Venture Partners, the company has raised $290 million from prominent healthcare investors to support its research and development initiatives. Metsera is advancing a diverse portfolio of oral and injectable therapies, including incretin, non-incretin, and combination treatments. These therapies target various aspects of weight loss and are developed from a proprietary library of over 20,000 gut hormone peptides and peptide/antibody conjugates. A notable partnership with Amneal Pharmaceuticals focuses on the development and supply of its investigational weight loss therapy, MET-097.